215 related articles for article (PubMed ID: 24855476)
21. Is fidaxomicin worth the cost? An economic analysis.
Bartsch SM; Umscheid CA; Fishman N; Lee BY
Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
[TBL] [Abstract][Full Text] [Related]
22. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
[TBL] [Abstract][Full Text] [Related]
23. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
27. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
28. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
[TBL] [Abstract][Full Text] [Related]
29. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
Zhanel GG; Walkty AJ; Karlowsky JA
Can J Infect Dis Med Microbiol; 2015; 26(6):305-12. PubMed ID: 26744587
[TBL] [Abstract][Full Text] [Related]
30. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
Whitney L; Nesnas J; Planche T
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
[TBL] [Abstract][Full Text] [Related]
31. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
32. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
[TBL] [Abstract][Full Text] [Related]
33. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
34. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
35. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
36. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
38. The Risk of
Hall RG; Cole TJ; Shaw C; Alvarez CA
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759
[TBL] [Abstract][Full Text] [Related]
39. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]